Telix to acquire ITM for $1.65B upfront plus up to $700M
Telix Pharmaceuticals said it will acquire 100% of ITM for $1.65B upfront and up to $700M in milestone payments tied to ITM-11 approvals and sales, subject to approvals. Closing is expected by end FY 2026.
Story updates
01:02:21 AM UTC
SquawkNews
Telix will acquire 100% of ITM for $1.65B upfront, plus up to $700M in milestones tied to ITM-11 approvals and sales, subject to approvals. Closing is expected by end FY 2026.Material DetailsContext by AI AnalystThis is a late-stage consolidation move to vertically integrate supply and add late-sta…
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) said it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE (“ITM”), described as a global leader in radioisotope p…